Literature DB >> 25518057

Prediction of endoscopic disease activity in ulcerative colitis by two different assays for fecal calprotectin.

Vendel Kristensen, Pasquale Klepp, Milada Cvancarova, Arne Røseth, Viggo Skar, Bjørn Moum.   

Abstract

BACKGROUND AND AIMS: As mucosal healing is the goal of treatment in inflammatory bowel disease, defining a fecal [f-] calprotectin cut-off level for mucosal healing is crucial. Previous studies have presented different cut-off levels. The aim of this study was to investigate the ability of two f-calprotectin assays to differentiate mucosal healing from inflammation in ulcerative colitis.
METHODS: Sixty-two patients with ulcerative colitis underwent colonoscopy for classification of mucosal inflammation [Mayo endoscopic subscore]. The patients also submitted a fecal sample for f-calprotectin analysis using two different assays, Calpro ELISA and Buhlmann ELISA.
RESULTS: The two assays correlated significantly, with a Spearman rank correlation coefficient of 0.86. Both assays showed significantly different f-calprotectin levels in patients with a Mayo endoscopic subscore of 0 [mucosal healing] and 1–3 [inflamed mucosa] [p <0.001]. Using ROC curve analyses, we selected the best cut-off levels for both assays with responding sensitivity and specificity [presented with 95% confidence intervals]; Calpro ELISA cut-off 61 μg/g, sensitivity 84.1% [75.0–93.2%], specificity 83.3 % [74.0–92.6%], and Buhlmann ELISA cut-off 96 μg/g, sensitivity 90.9 % [83.7–98.1%], specificity 83.3 % [74.0–92.6%]. Defining mucosal healing as a Mayo endoscopic subscore ≤1, cut-off levels increased: Calpro ELISA cut-off 110 μg/g, sensitivity 80.0%[70–90%], specificity 66.6 % [54.9–78.3%]; and Buhlmann ELISA cut-off 259 μg/g, sensitivity 83.3 %[74–92.6%], specificity 71.9 % [60.7–83.1%].
CONCLUSIONS: The study demonstrates the need for assay specific cut-off levels in clinical practice,as the f-calprotectin cut-off level for endoscopic disease activity differed in these two assays.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 25518057     DOI: 10.1093/ecco-jcc/jju015

Source DB:  PubMed          Journal:  J Crohns Colitis        ISSN: 1873-9946            Impact factor:   9.071


  15 in total

Review 1.  Current best practice for disease activity assessment in IBD.

Authors:  Alissa J Walsh; Robert V Bryant; Simon P L Travis
Journal:  Nat Rev Gastroenterol Hepatol       Date:  2016-09-01       Impact factor: 46.802

Review 2.  Practical guidance on the use of faecal calprotectin.

Authors:  Matthew J Brookes; Simon Whitehead; Daniel R Gaya; Antony Barney Hawthorne
Journal:  Frontline Gastroenterol       Date:  2017-02-22

3.  Optimal Range of Fecal Calprotectin for Predicting Mucosal Healing in Patients with Inflammatory Bowel Disease: A Systematic Review and Meta-Analysis.

Authors:  Bing-Jie Xiang; Min Jiang; Ming-Jun Sun; Cong Dai
Journal:  Visc Med       Date:  2021-01-21

Review 4.  Are faecal markers good indicators of mucosal healing in inflammatory bowel disease?

Authors:  Gudula Jam Boon; Andrew S Day; Chris J Mulder; Richard B Gearry
Journal:  World J Gastroenterol       Date:  2015-10-28       Impact factor: 5.742

5.  Incorporating Fecal Calprotectin Into Clinical Practice for Patients With Moderate-to-Severely Active Ulcerative Colitis Treated With Biologics or Small-Molecule Inhibitors.

Authors:  Parambir S Dulai; Robert Battat; Maria Barsky; Nghia H Nguyen; Christopher Ma; Neeraj Narula; Mahmoud Mosli; Niels Vande Casteele; Brigid S Boland; Larry Prokop; M Hassan Murad; Geert D'Haens; Brian G Feagan; William J Sandborn; Vipul Jairath; Siddharth Singh
Journal:  Am J Gastroenterol       Date:  2020-06       Impact factor: 12.045

6.  Fecal Calprotectin: A Reliable Predictor of Mucosal Healing after Treatment for Active Ulcerative Colitis.

Authors:  Vendel Kristensen; Arne Røseth; Tahir Ahmad; Viggo Skar; Bjørn Moum
Journal:  Gastroenterol Res Pract       Date:  2017-10-31       Impact factor: 2.260

7.  Fatigue is not associated with vitamin D deficiency in inflammatory bowel disease patients.

Authors:  Svein Oskar Frigstad; Marte Lie Høivik; Jørgen Jahnsen; Milada Cvancarova; Tore Grimstad; Ingrid Prytz Berset; Gert Huppertz-Hauss; Øistein Hovde; Tomm Bernklev; Bjørn Moum; Lars-Petter Jelsness-Jørgensen
Journal:  World J Gastroenterol       Date:  2018-08-07       Impact factor: 5.742

8.  High Prevalence of Vitamin D Deficiency among Patients with Inflammatory Bowel Disease.

Authors:  Daniel Caviezel; Silvia Maissen; Jan Hendrik Niess; Caroline Kiss; Petr Hruz
Journal:  Inflamm Intest Dis       Date:  2018-06-28

Review 9.  Faecal Calprotectin in Assessment of Mucosal Healing in Adults with Inflammatory Bowel Disease: A Meta-Analysis.

Authors:  Mariusz A Bromke; Katarzyna Neubauer; Radosław Kempiński; Małgorzata Krzystek-Korpacka
Journal:  J Clin Med       Date:  2021-05-19       Impact factor: 4.241

10.  Soluble ST2 is a sensitive clinical marker of ulcerative colitis evolution.

Authors:  David Díaz-Jiménez; Marjorie De la Fuente; Karen Dubois-Camacho; Glauben Landskron; Janitza Fuentes; Tamara Pérez; María Julieta González; Daniela Simian; Marcela A Hermoso; Rodrigo Quera
Journal:  BMC Gastroenterol       Date:  2016-08-26       Impact factor: 3.067

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.